Off-the-shelf CAR-T shows potential to delay lymphoma relapse in interim Phase 3 results
Allogene Therapeutics reported interim Phase 3 data for its off-the-shelf CAR-T therapy cema-cel in B-cell lymphoma, showing 58% MRD negativity in treated patients versus 16% in those observed with standard care, a result that could delay or prevent cancer relapse in high-risk patients, though the data are preliminary.
